White Papers

White Papers

Personalized (aka Precision) Therapy-A Systems Analysis of Captured Molecular Data

Date: May 1, 2017 | Source: Mary Crowley Cancer Research, Dallas, TX

There are eight hallmark biological capabilities necessary for cancer development and persistence: (1) sustained proliferation, (2) evasion of growth suppressors, (3) death resistance ...

Targeting Cancer

Date: January 22, 2015 | Source: Mary Crowley Cancer Research, Dallas, TX

The personalization of oncology treatments demands the alignment of patients’ molecular cancer growth mechanisms with the drugs which have been designed to target the cancer specific molecular signals.

Human Genome

Date: March 5, 2014 | Source: Mary Crowley Cancer Research, Dallas, TX

The most common way people give up their power is by thinking they don't have any.

Vaccine Insights from Ongoing Trials

Date: May 31, 2013 | Source: Mary Crowley Medical Research, Dallas, TX

Mary Crowley presented at the American Society of Clinical Oncology 2013 Annual Conference on May 31, 2013.

Melanoma

"Think about research for your advanced melanoma patient” - John Nemunaitis, MD

Clinical Update of bifunctional (bi)-shRNAi Nanoplex Technology in Cancer

Date: May 15, 2013 | Source: Mary Crowley Medical Research Center, Dallas, TX

Mary Crowley presented at the American Society of Gene and Cellular Therapy 2013 Annual Conference this May.

Clinical Update of bi-shRNA furin/GMCSF DNA Transfected Tumor Vaccine: FANG in Cancer Patients

Date: May 15, 2013 | Source: Mary Crowley Medical Research, Dallas, TX

Mary Crowley presented at the American Society of Gene and Cellular Therapy 2013 Annual Conference this May.

Molecular Mapping for Personalized Cancer Therapeutics

By: John J Nemunaitis MD

Date: November 22, 2011 | Source: Mary Crowley Medical Research Center, Dallas, TX

Our understanding of the biomolecular basis of cancer has virtually exploded over the last 10 years. Developments in genetics, molecular biology, and molecular pharmacology promise to dramatically alter strategies of cancer treatment. Clearly, previous therapeutic principles derived from cytotoxic based therapy now provide diminishing return with respect to patient benefit.

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients with Unresectable Metastatic Melanoma

By: Neil N. Senzer

Date: November 9, 2009 | Source: Journal of Clinical Oncology

Treatment options for metastatic melanoma are limited. We conducted this phase II trial to assess the efficacy of JS1/34.5-/47-/granulocyte-macrophage colony-stimulating factor (GM-CSF) in stages IIIc and IV disease.

Transforming Growth Factor Beta

By: John Nemunaitis MD

Date: September 21, 2006 | Source: Mary Crowley Cancer Research /Texas Oncology PA

Belagenpumatucel is a non-viral gene based allogeneic tumor cell vaccine which demonstrates enhancement of tumor antigen recognition as a result of TGF-β2 inhibition.

Celebrating 20 Years